Gold Silver Reports (GSR) – Cadila Healthcare Extends Gain After Zydus Gets FDA Nod — Shares of the drug maker extended gains for the second day and rose as much as 2.1 percent to Rs 397.35.
The pharmaceutical company’s Zydus unit received final approval from the U.S. drug regulator for its Tizanidine Tablets, used during the treatment of spinal chord, according to its stock exchange notification.
The stock declined 9.6 percent so far this year and a loss of 9.9 percent in the past 12 months. – Neal Bhai Reports (NBR)
